A Novel Nomogram to Predict Severity of COVID-19

Completed

• Conditions: COVID-19 Disease; Nomogram Model
• Interventions: Other: other

• Registration Number: NCT04366024
• Lead Sponsor: Xinqiao Hospital of Chongqing

Brief Summary

Investigators use clinical data from a large sample of COVID-19 disease patients to screen out biomarkers associated with disease severity. Then, a novel nomogram model will be established to predict covid-19 disease severity, which could provide important assistance and supplement for clinical work. In the case of extremely shortage of front-line medical resources, patients with potential severe diseases will be timely treated with the help of the novel nomogram model.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-17
• Study First Submitted: 2020-04-21
• Study First Submitted QC: 2020-04-27
• Study First Posted: 2020-04-28
• Primary Completion: 2020-08-30
• Study Completion: 2021-12-31
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-22
• Last Update Posted: 2024-02-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• COVID-19 disease patients confirmed by virus nucleic acid RT-PCR and CT

Exclusion Criteria

• unconfirmed suspected cases
• Patients during pregnancy and lactation
• incomplete clinical data
• investigators considered patients ineligible for the trial
• Child patients

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Observed group	other	COVID-19 disease patients who were detected by RT-PCR and CT imaging.

Primary Outcome Measures

Name	Time	Method
the consistency of predicted severe rate and observed severe rate of COVID-19 patients	up to 3 months	We aim to use the clinical data of COVID-19 patients to construct a nomogram model to predict the severe rate of each patient, then the the consistency of predicted severe rate and observed severe rate will be evaluated by calibration plot.
Duration of severe illness	up to 3 months	the duration of severe illness of each patient will evaluated

Trial Locations

Locations (1)

Xinqiao Hospital of Chongqing; 🇨🇳 Chongqing, Chongqing, China